Table 2a.

Disease-free survival by treatment arm and baseline sHER2 level

Arm	sHER2 Group	N=2318	#Events	HR*	95% CI	p-value	DFS
							3 yr	5 yr
All	<15	2029	277	1			87.3	81.9
	≥15	289	86	1.95	1.52–2.49	<0.0001	71.5	63.7
A	<15	684	117	1			83.6	76.5
	≥15	111	41	1.81	1.26–2.61	0.0014	64.7	56.1
B	<15	723	91	1			88.1	83.4
	≥15	91	25	2.08	1.32–3.27	0.0015	76.6	67.7
C	<15	622	69	1			90.7	86.3
	≥15	87	20	1.96	1.16–3.33	0.01	75.3	70.0
All	< 10.0	678	84	1			86.7	82.2
	10.0–11.5	536	70	0.91	0.66–1.25	0.57	88.8	84.1
	11.5–13.5	583	86	1.03	0.76–1.40	0.83	86.6	80.4
	≥ 13.5	521	123	1.57	1.19–2.08	0.002	78.2	70.6

^*Stratified by hormone receptor status and nodal status.